Cipla Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Cipla Ltd is up for a third straight session in a row. The stock is quoting at Rs 1288.9, up 4.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.75% on the day, quoting at 24195.15. The Sensex is at 77763.49, down 0.96%. Cipla Ltd has risen around 5.7% in last one month.

Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 30.64 lakh shares today, compared to the daily average of 18.9 lakh shares in last one month.

The benchmark April futures contract for the stock is quoting at Rs 1286.8, up 3.91% on the day. Cipla Ltd is down 16.94% in last one year as compared to a 0.21% drop in NIFTY and a 4.48% drop in the Nifty Pharma index.

The PE of the stock is 21.77 based on TTM earnings ending December 25.

The approval covers a product that is the first AB-rated generic therapeutic equivalent of Ventolin HFA, originally marketed by GlaxoSmithKline.

The drug is indicated for the treatment or prevention of bronchospasm in adults and children aged four years and above with reversible obstructive airway disease. It is also used to prevent exercise-induced bronchospasm in patients in the same age group.

Cipla said the approval strengthens its respiratory portfolio in the U.S. market. The company already has approved generics for both Ventolin HFA and Proventil HFA.

According to data from IQVIA, the total U.S. market for albuterol inhalers is estimated at around $1.5 billion.

The development is seen as a positive for Cipla?s U.S. business, particularly in the respiratory segment, where the company continues to expand its presence with a differentiated portfolio.

Commenting on the approval, Achin Gupta, Managing Director & Global CEO, Cipla, said: ?This marks an important milestone for Cipla and reflects our strong scientific and regulatory capabilities in complex inhalation products. Lung health remains at the heart of all our offerings and follows a singular, distilled objective, to build a sustainable and differentiated portfolio for patients globally.?

Marc Falkin, Chief Executive Officer, Cipla North America, added: ?Strengthening our U.S. respiratory franchise, the product will be manufactured at our newly constructed, dedicated inhalation facility in Fall River, Massachusetts, reinforcing both supply resilience and our domestic manufacturing footprint. With planned volume ramp-up, we expect to drive meaningful difference in the lives of patients.?

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The company reported 56.96% decrease in consolidated net profit to Rs 675.80 crore in Q3 FY26 as against Rs 1,570.51 crore in Q3 FY25. Total revenue from operations marginally rose 0.02% YoY to Rs 7,074.48 crore in Q3 FY26.

The inspection was a routine current good manufacturing practices (cGMP) inspection and a pre-approval inspection (PAI).

On conclusion of the inspection, the Company received two inspectional observations in Form 483.

The company will work closely with the US FDA and is committed to address these comprehensively within stipulated time,? Cipla said in a statement.

Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets.

The company reported 56.96% decrease in consolidated net profit to Rs 675.80 crore in Q3 FY26 as against Rs 1,570.51 crore in Q3 FY25. Total revenue from operations marginally rose 0.02% YoY to Rs 7,074.48 crore in Q3 FY26.

The scrip had added 0.61% to end at Rs 1238.30 on the BSE on Friday.

Cipla announced that that the USFDA has conducted an inspection at the Company's manufacturing facility in Verna, Goa from 6 to 17 April 2026. The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI). On conclusion of the inspection, the Company received two (2) inspectional observations in Form 483.